81 related articles for article (PubMed ID: 22340100)
1. [Expression of Cdc7 and mcm2 as a marker for proliferation and prognosis in diffuse large B cell lymphoma].
Hou Y; Wang HQ; Fu K; Zhang HL; Qian ZZ; Qiu LH; Li W; Zhou SY; Li LF; Hao XS
Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):911-5. PubMed ID: 22340100
[TBL] [Abstract][Full Text] [Related]
2. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis.
Obermann EC; Went P; Zimpfer A; Tzankov A; Wild PJ; Stoehr R; Pileri SA; Dirnhofer S
BMC Cancer; 2005 Dec; 5():162. PubMed ID: 16368013
[TBL] [Abstract][Full Text] [Related]
3. High expression of cell division cycle 7 protein correlates with poor prognosis in patients with diffuse large B-cell lymphoma.
Hou Y; Wang HQ; Ba Y
Med Oncol; 2012 Dec; 29(5):3498-503. PubMed ID: 22528513
[TBL] [Abstract][Full Text] [Related]
4. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma.
Bavi P; Abubaker J; Hussain A; Sultana M; Al-Dayel F; Uddin S; Al-Kuraya KS
Hum Pathol; 2008 Jun; 39(6):885-94. PubMed ID: 18400256
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer.
Yang C; Wen Y; Li H; Zhang D; Zhang N; Shi X; Jiang B; Ma X; Yang P; Tang H; Peng Z; Yang Y
Oncol Rep; 2012 Jan; 27(1):135-42. PubMed ID: 21947329
[TBL] [Abstract][Full Text] [Related]
6. Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka Lymphoma Study Group.
Wada N; Zaki MA; Kohara M; Ogawa H; Sugiyama H; Nomura S; Matsumura I; Hino M; Kanakura Y; Inagaki H; Morii E; Aozasa K
Histopathology; 2012 May; 60(6):924-32. PubMed ID: 22321065
[TBL] [Abstract][Full Text] [Related]
7. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
Rodins K; Cheale M; Coleman N; Fox SB
Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
[TBL] [Abstract][Full Text] [Related]
8. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy.
Li ZM; Huang JJ; Xia Y; Zhu YJ; Zhao W; Wei WX; Jiang WQ; Lin TY; Huang HQ; Guan ZZ
Eur J Haematol; 2012 Jun; 88(6):510-7. PubMed ID: 22413767
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
[TBL] [Abstract][Full Text] [Related]
10. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
[TBL] [Abstract][Full Text] [Related]
11. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective.
Talaulikar D; Shadbolt B; Bell J; Khan K; Dahlstrom JE; McDonald A; Pidcock M; Broomfield A
Histopathology; 2008 Feb; 52(3):340-7. PubMed ID: 18269585
[TBL] [Abstract][Full Text] [Related]
12. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
13. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma.
Hyo R; Tomita N; Takeuchi K; Aoshima T; Fujita A; Kuwabara H; Hashimoto C; Takemura S; Taguchi J; Sakai R; Fujita H; Fujisawa S; Ogawa K; Motomura S; Suzuki R; Ishigatsubo Y
Hematol Oncol; 2010 Mar; 28(1):27-32. PubMed ID: 19358143
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of p16INK4A, Ki-67, and Mcm2 proteins in gastrointestinal stromal tumors: prognostic implications and correlations with risk stratification of NIH consensus criteria.
Huang HY; Huang WW; Lin CN; Eng HL; Li SH; Li CF; Lu D; Yu SC; Hsiung CY
Ann Surg Oncol; 2006 Dec; 13(12):1633-44. PubMed ID: 17013685
[TBL] [Abstract][Full Text] [Related]
16. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab.
Natkunam Y; Farinha P; Hsi ED; Hans CP; Tibshirani R; Sehn LH; Connors JM; Gratzinger D; Rosado M; Zhao S; Pohlman B; Wongchaowart N; Bast M; Avigdor A; Schiby G; Nagler A; Byrne GE; Levy R; Gascoyne RD; Lossos IS
J Clin Oncol; 2008 Jan; 26(3):447-54. PubMed ID: 18086797
[TBL] [Abstract][Full Text] [Related]
17. MGMT methylation in diffuse large B-cell lymphoma: validation of quantitative methylation-specific PCR and comparison with MGMT protein expression.
Uccella S; Cerutti R; Placidi C; Marchet S; Carnevali I; Bernasconi B; Proserpio I; Pinotti G; Tibiletti MG; Furlan D; Capella C
J Clin Pathol; 2009 Aug; 62(8):715-23. PubMed ID: 19638543
[TBL] [Abstract][Full Text] [Related]
18. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group.
Shiozawa E; Takimoto M; Makino R; Adachi D; Saito B; Yamochi-Onizuka T; Yamochi T; Shimozuma J; Maeda T; Kohno Y; Kawakami K; Nakamaki T; Tomoyasu S; Shiokawa A; Ota H
Leuk Res; 2006 Jul; 30(7):859-67. PubMed ID: 16406514
[TBL] [Abstract][Full Text] [Related]
20. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
